Search | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Characterization of TP53 Mutations in Low-Grade Myelodysplastic Syndromes and Myelodysplastic Syndromes with a Non-Complex Karyotype

    ... OBJECTIVES: Although commonly associated with high-grade myelodysplastic syndrome (MDS) and MDS with a complex karyotype, TP53 mutations ... Bone Marrow Diseases:  myelodysplastic syndromes (MDS) ...

    Research Article last updated 10/02/2017 - 10:56am.

  2. Erythropoietin inhibits osteoblast function in myelodysplastic syndromes via the canonical Wnt pathway

    ... are controversially discussed. Since patients with myelodysplastic syndromes often display excessively high erythropoietin level, we aimed to ...

    Research Article last updated 11/08/2017 - 8:52am.

  3. Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen

    ... serious adverse event that occurred among 85 AML and myelodysplastic syndromes (MDS) patients treated in a prospective clinical study using ...

    Research Article last updated 11/08/2017 - 9:26am.

  4. Risk and timing of cardiovascular death among patients with myelodysplastic syndromes

    ... 31, 2017 Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders associated ...

    Research Article last updated 11/03/2017 - 10:36am.

  5. Pro-inflammatory proteins S100A9 and TNFα suppress erythropoietin elaboration in myelodysplastic syndromes

    ... innate immune activation in the pathobiology of myelodysplastic syndromes . A key myeloid related inflammatory protein, S100A9, serves as a ...

    Research Article last updated 10/20/2017 - 9:16am.

  6. Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitors

    ... Patients with lower-risk myelodysplastic syndromes (MDS) are mainly affected by chronic anemia and fatigue. ...

    Research Article last updated 10/23/2017 - 11:08am.

  7. Optimizing the use of hypomethylating agents in myelodysplastic syndromes: Selecting the candidate, predicting the response, and enhancing the activity

    ... June 23, 2017 Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell ...

    Research Article last updated 10/23/2017 - 11:00am.

  8. SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic Syndromes

    ... October 1, 2017 Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid neoplasms ...

    Research Article last updated 10/20/2017 - 9:14am.

  9. Relationship between lenalidomide dose modification, duration of therapy, and long-term outcomes in patients with myelodysplastic syndromes

    ... treatment-associated adverse events among patients with myelodysplastic syndromes (MDS) treated with lenalidomide ; such modifications are ...

    Research Article last updated 11/08/2017 - 9:12am.

  10. Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitors

    ... Patients with lower-risk myelodysplastic syndromes (MDS) are mainly affected by chronic anemia and fatigue. ...

    Research Article last updated 10/02/2017 - 10:10am.